Table 1

Baseline characteristics and spike-specific SARS-CoV-2 antibody titres in the New York City cohort

CharacteristicHealthy (n=26)IMID
No MTX (n=26)
IMID
Yes MTX (n=25)
P value
Age, mean (range, SD)49.2 (28–74, 11.9)49.1 (29–79, 14.9)63.2 (22–77, 11.9)<0.001
Female, n (%)16 (61.5)18 (69.2)18 (66.7)0.352
Race, n (%)0.220
 White16 (61.5)20 (76.9)17 (63.0)
 Black1 (3.8)2 (7.7)3 (11.1)
 Asian9 (34.6)3 (11.5)3 (11.1)
 Other0 (0.0)1 (3.8)2 (7.4)
Hispanic ethnicity, n (%)1 (3.8)3 (11.5)5 (18.5)0.200
Primary IMID, n (%)0.107
 Psoriasis and/or psoriatic arthritis--15 (57.7)9 (36.0)
 Rheumatoid arthritis--10 (38.5)12 (48.0)
 Other*--1 (3.8)4 (16.0)
Long-term medication, n (%)
 Methotrexate--0 (0.0)25 (100.0)--
 Tumour necrosis factor inhibitor--11 (42.3)9 (36.0)0.776
 Other anticytokines/Janus kinase inhibitors†--9 (34.6)1 (4.0)0.011
 Other oral immunomodulators‡--7 (26.9)6 (24.0)1.00
Methotrexate dose, mean (SD)----15.7 (5.0)
COVID-19 infection before vaccination, n (%)4 (15.4)5 (19.2)2 (8.0)0.509
Days from first vaccination dose, mean (range, SD)29.0 (23–44, 4.6)32.5 (25–45, 5.0)34.6 (21–73, 9.9)0.002
Number receiving second vaccination dose, n (%)26 (100.0)26 (100.0)25 (100.0)1.00
Adequate humoral response§¶, n (%)25 (96.1)24 (92.3)18 (72.0)0.023
Spike-specific SARS-CoV-2 antibody titres¶0.294
 Titre median (range)104 354 (141–601 185)113 608 (25–737 310)46 901 (25–694 528)
  • *Vasculitis, dermatomyositis, adult-onset Still’s disease, sarcoidosis and polymyalgia rheumatica.

  • †For IMID No MTX: IL-17i (3), IL-23i (2), abatacept (1), rituximab (1), JAKi (2). For IMID Yes MTX: IL-17 (1).

  • ‡For IMID No MTX: leflunomide (2), oral steroid (1), sulfasalazine (2), apremilast (1), hydroxychloroquine (1). For IMID Yes MTX: oral steroid (2), sulfasalazine (2), hydroxychloroquine (2).

  • §Adequate humoral response defined as greater than 5000 units.

  • ¶All values 1 week after second vaccination.

  • IMID, immune-mediated inflammatory disease; MTX, methotrexate.